Abstract
Results of several clinical trials have shown that verapamil is effective in reducing blood pressure (BP) in African Americans, a population at high risk for hypertension and target-organ damage. Nonetheless, adequate control of BP is perceived as difficult to achieve in this population. A post hoc analysis of data from the community-based CHRONO trial (Controlling Hypertension in the moRning with a ChrONO medication) was undertaken to assess racial/ethnic differences in the safety and efficacy of the Chronotherapeutic Oral Drug Absorption System (CODAS) formulation of verapamil in a real-world setting. Once-daily administration of the CODAS formulation of verapamil significantly reduced morning BP (P<0.0001) regardless of race or ethnicity. In the African-American population (N=466), the response rate for systolic BP (<140 mmHg or > or =10% reduction from baseline) and diastolic BP (<90 mmHg or reduction > or =10 mmHg from baseline) combined was 70.8%, and 60% of those individuals responded at the lowest (200 mg) dose. Of the 59.7% of African Americans who reached the target BP of <140/90 mmHg, 64% did so at the 200-mg dose. Response rates were not affected by gender, age or treatment history, and CODAS-verapamil was well tolerated in all ethnic/racial treatment groups. In a trial conducted in actual clinical practices, the CODAS formulation of verapamil was shown to be safe and effective in African Americans, Caucasians, Hispanics and Asians.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bakris G. L., Mangrum A., Copley J. B., Vicknair N., Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997 Mar;29(3):744–750. doi: 10.1161/01.hyp.29.3.744. [DOI] [PubMed] [Google Scholar]
- Bakris George, Sica Dominic, Ram Venkata, Fagan Timothy, Vaitkus Paul T., Anders Robert J. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens. 2002 Jan;15(1 Pt 1):53–57. doi: 10.1016/s0895-7061(01)02254-3. [DOI] [PubMed] [Google Scholar]
- Chobanian Aram V., Bakris George L., Black Henry R., Cushman William C., Green Lee A., Izzo Joseph L., Jr, Jones Daniel W., Materson Barry J., Oparil Suzanne, Wright Jackson T., Jr The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 14;289(19):2560–2572. doi: 10.1001/jama.289.19.2560. [DOI] [PubMed] [Google Scholar]
- Cubeddu L. X., Aranda J., Singh B., Klein M., Brachfeld J., Freis E., Roman J., Eades T. A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. JAMA. 1986 Oct 24;256(16):2214–2221. [PubMed] [Google Scholar]
- Douglas Janice G., Bakris George L., Epstein Murray, Ferdinand Keith C., Ferrario Carlos, Flack John M., Jamerson Kenneth A., Jones Wendell E., Haywood Julian, Maxey Randall. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003 Mar 10;163(5):525–541. doi: 10.1001/archinte.163.5.525. [DOI] [PubMed] [Google Scholar]
- Giles Thomas D., Bakris George L., Smith David H. G., Davidai Giora, Weber Michael A. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens. 2003 Jun;16(6):460–466. doi: 10.1016/s0895-7061(03)00848-3. [DOI] [PubMed] [Google Scholar]
- Hall W. D. A rational approach to the treatment of hypertension in special populations. Am Fam Physician. 1999 Jul;60(1):156–162. [PubMed] [Google Scholar]
- Pepine Carl J., Handberg Eileen M., Cooper-DeHoff Rhonda M., Marks Ronald G., Kowey Peter, Messerli Franz H., Mancia Giuseppe, Cangiano José L., Garcia-Barreto David, Keltai Matyas. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 3;290(21):2805–2816. doi: 10.1001/jama.290.21.2805. [DOI] [PubMed] [Google Scholar]
- Prisant L. Michael, Black Henry R., Messerli Franz, Weber Michael. Chrono: a community-based hypertension trial of a chronotherapeutic formulation of verapamil. Am J Ther. 2002 Nov-Dec;9(6):476–483. doi: 10.1097/00045391-200211000-00003. [DOI] [PubMed] [Google Scholar]
- Sareli P., Radevski I. V., Valtchanova Z. P., Libhaber E., Candy G. P., Den Hond E., Libhaber C., Skudicky D., Wang J. G., Staessen J. A. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. Arch Intern Med. 2001 Apr 9;161(7):965–971. doi: 10.1001/archinte.161.7.965. [DOI] [PubMed] [Google Scholar]
- Saunders E., Weir M. R., Kong B. W., Hollifield J., Gray J., Vertes V., Sowers J. R., Zemel M. B., Curry C., Schoenberger J. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990 Aug;150(8):1707–1713. [PubMed] [Google Scholar]
- White W. B., Johnson M. F., Black H. R., Fakouhi T. D. Effects of the chronotherapeutic delivery of verapamil on circadian blood pressure in African-American patients with hypertension. Ethn Dis. 1999 Autumn;9(3):341–349. [PubMed] [Google Scholar]